JUAN JOSÉ
LAHUERTA PALACIOS
Chercheur jusqu' 2020
Hospital San Pedro de Alcántara
Cáceres, EspañaPublications en collaboration avec des chercheurs de Hospital San Pedro de Alcántara (11)
2019
-
Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role (Leukemia, (2018), 32, 11, (2427-2434), 10.1038/s41375-018-0072-6)
Leukemia
-
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Blood Cancer Journal, Vol. 9, Núm. 4
2018
-
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
Leukemia, Vol. 32, Núm. 11, pp. 2427-2434
2016
-
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Blood, Vol. 127, Núm. 25, pp. 3165-3174
-
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
Blood, Vol. 127, Núm. 4, pp. 420-425
2015
-
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69
2014
-
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?
Blood, Vol. 124, Núm. 12, pp. 1887-1893
2012
-
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Blood, Vol. 120, Núm. 13, pp. 2581-2588
2011
-
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
Blood, Vol. 118, Núm. 17, pp. 4547-4553
2010
-
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial
The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941